InventisBio (SH:688382) Xin Lang Cai Jing·2025-08-27 03:15Company Overview - Yifang Biotechnology (Shanghai) Co., Ltd. was established on January 11, 2013, and went public on July 25, 2022. The company is located in the China (Shanghai) Free Trade Zone and focuses on the research, production, and sales of innovative drugs. Its main revenue source is 100% from technology licensing and cooperation [1]. Stock Performance - On August 27, Yifang Biotechnology's stock fell by 5.03%, trading at 37.96 CNY per share, with a total transaction volume of 326 million CNY and a turnover rate of 2.00%. The company's total market capitalization is 21.953 billion CNY [1]. Fund Holdings - According to data, one fund under China Ocean Fund holds a significant position in Yifang Biotechnology. The China Ocean Medical Mixed A Fund (000878) held 578,400 shares in the second quarter, accounting for 5.99% of the fund's net value, making it the eighth-largest holding. The estimated floating loss for today is approximately 1.1626 million CNY [2]. Fund Manager Performance - The fund manager of China Ocean Medical Mixed A Fund is Liang Jingjing, who has been in the position for 5 years and 49 days. The fund's total asset size is 811 million CNY. During Liang's tenure, the best fund return was -12.8%, while the worst was -24.97% [3].